Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic and endocrine disorders. Company press releases highlight progress across a pipeline that includes VK2735 for obesity and related metabolic conditions, VK2809 for lipid and liver disorders such as NASH and NAFLD, VK0214 for X-linked adrenoleukodystrophy (X-ALD), and an emerging program of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic diseases.
For VK2735, Viking regularly issues news on clinical milestones in both subcutaneous and oral tablet formulations. Recent announcements describe positive Phase 2 VENTURE trial results in obesity, with statistically significant weight loss and encouraging safety and tolerability, as well as Phase 2 VENTURE-Oral Dosing data showing meaningful weight reduction after 13 weeks of once-daily oral therapy. Additional releases cover the initiation and progress of the Phase 3 VANQUISH-1 and VANQUISH-2 trials, which evaluate weekly subcutaneous VK2735 in adults with obesity or overweight, including those with type 2 diabetes, over 78 weeks.
News items also detail exploratory maintenance dosing studies of VK2735 that examine monthly subcutaneous, weekly oral, and daily oral regimens following initial weight loss. Beyond obesity, Viking’s updates discuss VK2809’s Phase 2b success in biopsy-confirmed NASH and fibrosis, as well as Phase 2a results in NAFLD with elevated LDL-C, and VK0214’s Phase 1b data in X-ALD showing reductions in very long-chain fatty acids. Investors following VKTX news can expect coverage of clinical data presentations at scientific meetings, participation in healthcare and investor conferences, and SEC-reported corporate updates on financial results and pipeline status.
Viking Therapeutics (VKTX) has entered a multi-year strategic partnership with CordenPharma for the development and manufacturing of its GLP-1 drug candidate VK2735. The partnership encompasses the full supply chain from drug substance to drug product for both subcutaneous and oral peptide formulations.
CordenPharma will provide large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance, along with fill-finish services for the subcutaneous formulation and oral solid dosage manufacturing. The agreement leverages CordenPharma's global network of manufacturing facilities, featuring built-in redundancy through multiple drug substance sites to ensure uninterrupted supply throughout the product lifecycle.
Viking Therapeutics (NASDAQ: VKTX) has secured a major manufacturing agreement with CordenPharma for its VK2735 obesity treatment program. The multi-year contract ensures dedicated production capacity for both subcutaneous and oral formulations to support potential multi-billion-dollar annual product sales.
The agreement includes:
- Annual production capacity for multiple metric tons of VK2735 API
- 100 million autoinjectors and 100 million vial/syringe products annually
- Over 1 billion oral tablets manufacturing capacity per year
Viking will make prepayments totaling $150 million between 2025-2028, which will be credited against future orders. The company maintains all global rights to VK2735 and expects standard pharmaceutical product margins. Currently, VK2735 is in Phase 2 VENTURE-Oral Dosing Trial, with Phase 3 development for the subcutaneous formulation planned for Q2 2025.
Viking Therapeutics (NASDAQ: VKTX) has announced its participation in two major upcoming investor conferences in March 2025. The company will attend the Leerink Partners Global Healthcare Conference 2025 from March 10-12, where management will engage in a fireside chat on March 11 from 9:20 to 9:50 a.m. Eastern, along with one-on-one meetings.
Additionally, Viking management will participate in the Jefferies Biotech on the Beach Summit from March 11-12, 2025, conducting one-on-one meetings. Both events will take place in Miami, FL. A live webcast of the Leerink presentation will be available through Viking's website in the Investors & Media section, with a replay accessible post-conference.
Viking Therapeutics (VKTX) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical pipeline. The company plans to initiate Phase 3 studies for its obesity treatment VK2735 in Q2 2025, following positive Phase 2 VENTURE study results showing up to 14.7% body weight reduction. A Phase 2 trial for an oral version of VK2735 is currently underway.
Financial highlights include a strong cash position of $903 million at year-end 2024. The company reported a Q4 net loss of $35.4 million ($0.32 per share) and full-year net loss of $110.0 million ($1.01 per share). R&D expenses increased to $101.6 million for 2024, up from $63.8 million in 2023.
Viking Therapeutics (NASDAQ: VKTX) has scheduled its fourth quarter and year-end 2024 financial results release for February 5, 2025, after market close. The clinical-stage biopharmaceutical company, which focuses on developing novel therapies for metabolic and endocrine disorders, will host a conference call at 4:30 p.m. Eastern Time on the same day.
Participants can join the call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 internationally. A replay will be available until February 12, 2025, accessible by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (international) with replay code #6731266. The webcast will be available on Viking's website and archived for 30 days.
Viking Therapeutics (NASDAQ: VKTX) has initiated a Phase 2 VENTURE-Oral Dosing Trial for VK2735, their dual GLP-1 and GIP receptor agonist in tablet form. The 13-week study will evaluate safety, tolerability, pharmacokinetics, and weight loss efficacy in approximately 280 adults who are obese or overweight with comorbidities.
Previous 28-day Phase 1 results showed promising outcomes, with participants experiencing dose-dependent weight reductions up to 8.2%, and persistent effects up to 8.3% four weeks post-treatment. Up to 100% of treated subjects achieved ≥5% weight loss, compared to 0% for placebo. The treatment demonstrated good tolerability, with 99% of adverse events being mild or moderate.
Concurrently, Viking is advancing a subcutaneous formulation of VK2735, which showed significant results in its Phase 2 VENTURE study, with weight reductions up to 14.7%. The company plans to initiate Phase 3 development for the subcutaneous formulation in first half of 2025.
Viking Therapeutics (NASDAQ: VKTX) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. The company's CEO, Brian Lian, Ph.D., will deliver a corporate presentation on Monday, January 13, 2025, from 1:30 to 2:10 p.m. Pacific time at The Westin St. Francis San Francisco on Union Square.
The presentation will be accessible via live webcast through the Viking Therapeutics website's Investors & Media section under Webcasts. A replay will be available on the company's website after the conference. Dr. Lian will also participate in one-on-one meetings during the event.
Viking Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing novel therapies for metabolic and endocrine disorders.
Viking Therapeutics announced final 52-week results from its Phase 2b VOYAGE study of VK2809 in NASH/MASH patients. The drug achieved primary and secondary endpoints with significant liver fat reductions ranging from 37% to 55% at Week 52. NASH resolution rates were 63-75% in treated groups versus 29% for placebo. Patients showed fibrosis improvement of 44-57% compared to 34% for placebo. The drug demonstrated promising safety profile with 94% of treatment-related adverse events being mild or moderate. Additionally, VK2809 showed 20-25% placebo-adjusted reductions in LDL-C and improvements in other cardiovascular markers.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, will present results from its Phase 2b clinical trial of VK2809 at the 75th Liver Meeting® 2024. The study focuses on patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH). The oral presentation is scheduled for November 19, 2024, at the San Diego Convention Center. The trial, titled 'Results from the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A Randomized, Placebo-Controlled Trial,' will be presented by Dr. Rohit Loomba, Director of the NAFLD Research Center and Professor of Medicine at the University of California, San Diego.
Viking Therapeutics presented new clinical data from its VK2735 obesity program at ObesityWeek® 2024. The oral tablet formulation showed up to 8.2% weight loss from baseline (6.8% placebo-adjusted) after 28 days of dosing, with effects persisting up to Day 57. The subcutaneous formulation demonstrated up to 14.7% weight loss after 13 weeks in the VENTURE Phase 2 study, with maintenance effects lasting up to 7 weeks post-treatment. Both formulations showed encouraging tolerability with mainly mild adverse events. The company plans to discuss the injectable VK2735's clinical path with FDA and initiate a Phase 2 study for the oral formulation by year-end.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
